article thumbnail

Study Finds Olezarsen Cuts Triglyceride Levels by About Half

DAIC

adults—and more than 2 in 5 adults aged 60 years and older—have elevated triglycerides, also known as hypertriglyceridemia , putting them at an increased risk for heart attacks and stroke. milla1cf Sun, 04/07/2024 - 18:20 April 7, 2024 — An estimated 1 in 5 U.S.

article thumbnail

Findings from MOST Trial Presented at ISC24: Blood thinners added to clot-busting medication did not improve stroke outcomes

DAIC

Findings from the highly-anticipated MOST (Multi-Arm Optimization of Stroke Thrombolysis) trial were presented on the first day of the American Stroke Association’s International Stroke Conference, ISC 2024, being held through Feb. A lot of our approaches in stroke treatment were learned from how we treat heart attacks.

Stroke 105
article thumbnail

Generalisability of trials on antithrombotic treatment intensification in patients with cardiovascular disease

Heart BMJ

Methods Inclusion and exclusion criteria of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS), Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA), Prevention of Cardiovascular events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background (..)

article thumbnail

Inclusivity in randomised clinical trials: myth or reality?

Heart BMJ

In this issue of Heart, Castelijns et al aimed to apply the inclusion and exclusion criteria from the Cardiovascular Outcomes for People Using Anticoagulation Strategies, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance trials, Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using (..)

article thumbnail

The “open data” movement runs aground on FOURIER

Dr. Anish Koka

LDL floats around in the blood stream and is thought to incrementally accumulate on blood vessels in the body, ultimately increasing the risk of heart attacks and strokes. The positive results described were driven almost entirely by fewer heart attacks, and fewer revascularization procedures in the evolucumab arm.